Morgan Stanley Global Endurance C holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
Morgan Stanley Global Endurance Portfolio Class C MSJCX
- NAV / 1-Day Return $19.15 / −0.57 %
- Fund Size $13.7M
- Adjusted Expense Ratio 2.100%
- Net Expense Ratio 2.100%
- Fee Level: Distribution Above Average
- Share Class Type Level Load
- Morningstar Category Global Small/Mid Stock
- Equity Style Box (Funds) Small Value
- Minimum Initial Investment $1,000
- Investment Status Open
- TTM Yield 0.00%
- Turnover Ratio 176%
Morningstar’s Analysis MSJCX
Will MSJCX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 61.2
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Victoria PLC | 18.88 | 3M | Consumer Cyclical |
Roivant Sciences Ltd Ordinary Shares | 7.19 | 1M | Healthcare |
Arbutus Biopharma Corp | 5.45 | 893,410 | Healthcare |
QXO Inc | 4.95 | 811,918 | Industrials |
Immunovant Inc | 4.81 | 789,056 | Healthcare |
Floor & Decor Holdings Inc Class A | 4.78 | 784,383 | Consumer Cyclical |
Teleflex Inc | 4.08 | 668,279 | Healthcare |
Royalty Pharma PLC Class A | 3.79 | 621,087 | Healthcare |
DraftKings Inc Ordinary Shares - Class A | 3.66 | 600,556 | Consumer Cyclical |
Calumet Inc | 3.59 | 589,071 | Basic Materials |